Drug-Resistant Epilepsy (DRE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Drug-Resistant Epilepsy (DRE) Market Outlook

Thelansis’s “Drug-Resistant Epilepsy (DRE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Drug-Resistant Epilepsy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Drug-Resistant Epilepsy (DRE) Overview

Drug-Resistant Epilepsy (DRE) is characterized by the involvement of neuroinflammatory, autoimmune, and neurodegenerative mechanisms. Neuroinflammation induces immune, pathophysiological, biochemical, and psychological alterations, leading to aberrant neural connectivity and hyperexcitability within neural networks. Despite treatment with anti-epileptic drugs, administered either individually or in combination, sustained seizure control is often elusive due to the impact of inflammatory mediators on the endothelium of cerebral vessels. This disruption results in compromised endothelial integrity, abnormal angiogenesis, and increased blood-brain barrier permeability. Drug resistance emerges in 30% to 40% of patients with DRE, contributing to premature mortality and neuronal damage. DRE can manifest at any age following the onset of epilepsy and is associated with a diminished quality of life, heightened medical, social, and financial burdens, and elevated mortality rates.

• Epilepsy affects approximately 1.0% of the global population, with a slightly higher prevalence among males compared to females.
• The majority of epilepsy patients have a favorable prognosis, with 55–68% achieving long-term remission.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: